Insmed's Arikayce missed the primary endpoint in a Phase II clinical trial for the treatment of non-tuberculous mycobacterial (NTM) lung infections, but the company emphasized significant results for the trial's secondary endpoint to keep its stock from taking a very steep dive.
Monmouth Junction, New Jersey-based Insmed will discuss the data with US and EU regulators to determine the next steps for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?